Together, these studies comprehensively define the KRASi-induced proteome and identify ALPP/ALPPL2 as a promising cell surface target for combination with KRASi to enhance response and forestall KRASi resistance.
Jonathan M. DeLiberty, Fan-Yi Kong, Qi-Jia Yu et al.· bioRxiv· 0 citations
It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.
Sarah Kang, M. Parikh, Leontios Pappas et al.· Cancer Research· 0 citations
Pancreatic re-RT is feasible and may offer promising local control and time off chemotherapy for selected patients, and improvements in RT delivery with online adaptive therapy may further minimize toxicity.
Helen X. Hou, Hannah J. Roberts, P. Pathak et al.· American Journal of Clinical...· 0 citations
Direct inhibition of oncogenic RAS has emerged as a clinically active therapeutic strategy for RAS-addicted cancers, including pancreatic ductal adenocarcinoma (PDAC). However, resistance is likely to limit the durability of therapeutic response, motivating combination strategies that target adaptive survival mechani...
Joshua H. Choe, Kyle J. Seamon, Julien Dilly et al.· Cancer Research· 0 citations
The adaptive response to KRASG12C inhibitors (KRASi) in KRASG12C-mutant lung adenocarcinoma models is profile using an integrated genetic, transcriptomic, and mass-spectrometry-based quantitative temporal proteomic platform.
A. Padhye, Kalisa Kang, Fan-Yi Kong et al.· bioRxiv· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cell· 0 citations
Recent studies have identified a high prevalence of low grade pancreatic intraepithelial neoplasia (PanIN) in the pancreata of healthy adults. This study aimed to characterize the transcriptomic landscape of human PanINs at single cell resolution, with the goal of identifying hallmarks of initiation and progressi...
C. Nguyen, Anders W. Ohman, Winston R. Becker et al.· Cancer Research· 0 citations
IL-21-elicited CD4 T cells exert anti-tumor activity in mice, and potentially in humans, which can convert transient responses to KRAS inhibition into durable remissions in pancreatic cancer.
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cancer Research· 0 citations
These studies establish a comprehensive proteomic resource for the PDAC/KRASi research community and identify ALPP/ALPPL2 as a promising cell surface target for combination with KRASi to drive deeper, sustained responses and prevent or forestall KRASi resistance.
Jonathan M. DeLiberty, Fan-Yi Kong, Qi-Jia Yu et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.